EDSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EDSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Edesa Biotech's sale of business for the three months ended in Jun. 2024 was $0.00 Mil. It means Edesa Biotech gained $0.00 Mil from selling business. Edesa Biotech's sale of business for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.
Compared with last quarter ($0.00 Mil in Mar. 2024 ), Edesa Biotech gained the same money from selling business in Jun. 2024 ($0.00 Mil).
The historical data trend for Edesa Biotech's Sale Of Business can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edesa Biotech Annual Data | |||||||||||||||||||||
Trend | Aug14 | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
Sale Of Business | Get a 7-Day Free Trial | 6.39 | - | - | - | - |
Edesa Biotech Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Sale Of Business | Get a 7-Day Free Trial | - | - | - | - | - |
The amount earned to sell business.
Sale Of Business for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Edesa Biotech's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.
Pardeep Nijhawan | director, 10 percent owner, officer: Chief Executive Officer | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Stephen Lemieux | officer: Chief Financial Officer | 100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6 |
Joan Chypyha | director | 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Patrick Marshall | director | 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Van Der Velden Peter | director, 10 percent owner | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Michael J Brooks | officer: President | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Jennifer M Chao | director | 7 PURITAN WOODS ROAD, RYE NY 10580 |
Frank R. Oakes | director, officer: President, CEO, & Director | C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041 |
Sean Arthur Macdonald | director | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Lorin K Johnson | director | 3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303 |
Pardeep Nijhawan Medicine Professional Corp | 10 percent owner | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Paul William Pay | director | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Carlo Sistilli | director | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Lumira Capital Investment Management Inc. | 10 percent owner | 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5 |
Daniel E. Morse | director | C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041 |
From GuruFocus
By Marketwired • 10-21-2024
By ACCESSWIRE • 07-26-2023
By ACCESSWIRE • 10-10-2023
By Marketwired • 10-31-2024
By ACCESSWIRE ACCESSWIRE • 05-12-2023
By ACCESSWIRE • 12-16-2023
By ACCESSWIRE • 03-22-2024
By ACCESSWIRE • 06-27-2023
By ACCESSWIRE • 03-07-2024
By ACCESSWIRE • 04-02-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.